A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

NCT04573192 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

142

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: L19TNF
DRUG: Lomustine

Sponsor

Philogen S.p.A.